A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma

Condition:   Solitary Bone Plasmacytoma Interventions:   Drug: Durvalumab;   Radiation: Radiation therapy Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation Not yet recruiting - verified June 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials